top of page

Another Breakthrough For Precision Diagnostics

Oxford BioDynamics, a biotechnology developer of precision medicine tests based on novel epigenetic biomarkers, has joined forces with Professor Jaime Modiano of the University of Minnesota to develop the EpiSwitch Specific Canine Blood test, a blood-based tool capable of diagnosing Canine Hemangiosarcoma and five other common types of canine cancer.


a brown dog with its head out of a car window


The EpiSwitch SCB test is based on OBD's non-invasive array platform, using a 3D genomic approach to diagnose and support upgrades for additional diagnostic profiles. It aims to assist veterinary professionals in diagnosing cancer, minimizing unnecessary toxicity, making well-informed treatment decisions, and optimizing cost and resource management.


The test was validated using thorough 3D whole-genome profiling from peripheral blood. It demonstrated high sensitivity and specificity for lymphomas and sarcomas, with an accuracy exceeding 80%. It also showed high sensitivity and specificity for individual indications, with an accuracy greater than 89%. Currently, it will be offered to a limited number of veterinarians to generate real utility data and validation.


The EpiSwitch SCB sets itself apart from other non-invasive methods for canine cancer detection by being able to differentiate between different types of cancers, instead of just providing a basic 'cancer' or 'no cancer' result. It has the potential to enhance the precision and management of canine cancer patients.


“My first use of the (...) test helped navigate a very complex case of canine cancer relapse in the absence of options from the current standards of care. This test opens possibilities for a quick and reliable diagnosis in the various cases where time is at a premium,” Sara Fritz, DVM, stated in the news release.


Cancer is the primary cause of death for senior dogs, and Professor Modiano highlights the need to create precise diagnostic tools that can provide answers without relying on invasive biopsy procedures. Developers such as Oxford BioDynamics are making significant contributions to strive for a future where fast and accurate diagnosis is commonplace in every veterinary clinic.

Comments


bottom of page